Equities

AnGes Inc

AnGes Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)47.00
  • Today's Change1.00 / 2.17%
  • Shares traded408.60k
  • 1 Year change-57.27%
  • Beta1.9688
Data delayed at least 20 minutes, as of May 17 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

  • Revenue in JPY (TTM)249.94m
  • Net income in JPY-6.35bn
  • Incorporated1999
  • Employees145.00
  • Location
    AnGes IncSaito Bio-Incubator, 7-7-15, Saito-AsagiIBARAKI-SHI 567-0085JapanJPN
  • Phone+81 357302641
  • Websitehttps://www.anges.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kohjin Bio Co Ltd4.77bn384.98m7.65bn157.0018.171.9018.771.6084.0084.001,039.24802.50----------------39.44--8.07--1.14--0.4249--0.5715---53.61------
Wakamoto Pharmaceutical Co Ltd7.98bn-177.67m8.57bn292.00--0.729636.841.07-5.12-5.12229.89337.150.5252.082.8827,324,600.00-1.17-2.58-1.34-3.0046.9853.08-2.23-4.333.45--0.0085--3.31-4.50-42.041.88-17.490.00
CanBas Co Ltd (Parent)0.00-1.09bn9.35bn12.00--3.12-----64.47-64.470.00166.100.00----0.00-43.91-65.86-45.99-79.11-------1,094.10----0.00-------45.41------
TMS Co Ltd0.00-960.04m9.63bn14.00--2.79-----25.89-25.890.0085.770.00-------26.14---26.78-----------------------11.51------
Tsubota Laboratory Inc673.53m-641.32m9.64bn10.00--7.05--14.32-25.15-25.1526.4253.450.27112.0437.74---25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
Linical Co Ltd12.52bn680.40m10.09bn759.0013.541.188.490.806330.1230.12554.28346.380.7251--3.9916,494,230.003.944.716.557.2333.1031.605.435.98--17,809.030.279345.368.326.5527.06-4.97-33.014.94
AnGes Inc249.94m-6.35bn10.58bn145.00--0.3777--42.32-32.62-32.621.29124.450.00770.08624.771,723,752.00-19.47-28.50-23.06-33.1439.8539.42-2,540.59-6,726.820.9124--0.0139--128.13-24.1749.45--12.11--
3-D Matrix Ltd3.74bn-1.06bn10.61bn108.00--16.79--2.84-14.90-14.9054.067.740.66530.46545.1934,630,130.00-18.91-57.69-23.28-77.3164.0440.76-28.43-205.342.33--0.8717--53.6358.87-29.09---7.69--
KOEI CHEMICAL COMPANY, LIMITED19.43bn299.18m11.12bn387.0037.110.50894.760.572661.1761.173,971.904,460.940.49571.663.80--0.76593.150.9973.9427.1725.241.555.850.6907115.660.320743.884.441.19-56.72-20.82-3.2910.76
Medinet Co Ltd711.82m-1.40bn11.80bn98.00--2.12--16.58-6.00-6.003.0321.730.12411.343.787,263,510.00-24.31-21.05-25.48-22.4715.2528.75-196.06-135.4020.08--0.00--4.40-7.90-14.66---17.67--
ReproCell Inc2.43bn-31.42m11.81bn92.00--1.41155.684.87-0.3465-0.346528.3493.450.27885.415.60---0.3609-7.35-0.3932-8.0046.1939.83-1.29-27.1610.54-------17.8317.3989.71--13.27--
Stella Pharma Corp269.49m-763.75m11.87bn46.00--4.99--44.03-24.63-24.638.7076.120.06610.05083.98---18.74-22.50-21.00-24.8380.63---283.40-488.655.52-379.390.2819--17.65--1.94---5.87--
RaQualia Pharma Inc1.90bn-323.66m12.83bn67.00--2.10--6.75-14.99-14.9987.98283.050.28963.133.1528,376,150.00-4.932.13-5.292.2687.1188.49-17.025.3212.35--0.05670.00-34.8520.62-144.74--0.0967--
Nano Mrna Co Ltd135.51m-780.00m12.95bn17.00--3.79--95.58-11.10-11.101.9348.610.02559.029.66---14.37-24.16-15.59-25.1781.8884.69-575.61-600.709.17--0.2448---32.98-22.8840.50------
Healios KK124.00m-5.52bn12.98bn64.00--3.51--104.67-72.60-72.601.7041.050.0078--0.37131,937,500.00-34.77-23.55-52.02-28.5281.45---4,440.32-6,580.16---1.900.6824--34.44--26.04---22.00--
Data as of May 17 2024. Currency figures normalised to AnGes Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.62%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 09 May 20241.08m0.49%
SSgA Funds Management, Inc.as of 09 May 2024109.70k0.05%
Dimensional Fund Advisors LPas of 30 Apr 202480.10k0.04%
SPARX Asset Management Co., Ltd.as of 10 Mar 202247.30k0.02%
Dimensional Fund Advisors Ltd.as of 09 May 202425.59k0.01%
BlackRock Investment Management (UK) Ltd.as of 31 Jul 20230.000.00%
More ▼
Data from 28 Mar 2024 - 16 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.